NCT06090266: An ongoing trial by OncoResponse, Inc.
This trial is ongoing. It must report results 1 year, 7 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06090266 |
|---|---|
| Title | A Phase 1/2 Study of OR502 Alone and in Combination With Other Anti-cancer Agents in Subjects With Advanced Malignancies |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Oct. 24, 2023 |
| Completion date | Aug. 1, 2026 |
| Required reporting date | Aug. 1, 2027, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |